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Abstract
Identiﬁcation of latent tuberculosis (TB) infection and preventive therapy is important for TB control, especially in high-risk populations.
Since the advent of interferon-c release assays (IGRAs), many studies have evaluated their role in the diagnosis of active and latent TB.
With the growing evidence base, many guidelines now include IGRAs. We surveyed the literature and contacted experts to identify 33
guidelines and position papers from 25 countries and two supranational organizations. The results show considerable diversity in the
recommendations on IGRAs, with four approaches commonly proposed: (i) two-step approach of tuberculin skin test (TST) ﬁrst, fol-
lowed by IGRA either when the TST is negative (to increase sensitivity, mainly in immunocompromised individuals), or when the TST is
positive (to increase speciﬁcity, mainly in bacillus Calmette–Gue´rin-vaccinated individuals); (ii) Either TST or IGRA, but not both; (iii)
IGRA and TST together (to increase sensitivity); and (iv) IGRA only, replacing the TST. Overall, the use of IGRAs is increasingly recom-
mended, but most of the current guidelines do not use objective, transparent methods to grade evidence and recommendations, and
do not disclose conﬂicts of interests. Future IGRA guidelines must aim to be transparent, evidence-based, periodically updated, and free
of ﬁnancial conﬂicts and industry involvement.
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Introduction
Tuberculosis (TB) is a major global public health problem.
More than 9.4 million new TB cases were reported in 2009,
and 1.7 million people died from TB in that year. Although in
the high-incidence settings TB is mostly the result of recent
acquisition of Mycobacterium tuberculosis [1], the epidemiology
in low-incidence countries is different and a large proportion
of TB disease is the result of reactivation of latent TB [2].
Detection and management of latent tuberculosis infection
(LTBI) therefore is a key component of TB control in low-
incidence countries. In high-incidence countries screening for
LTBI has a role in high-risk groups such as the human immu-
nodeﬁciency virus (HIV)-infected individuals and child con-
tacts of people with TB.
Diagnosis of LTBI relies on immunodiagnostic methods,
which include one of the oldest tests in medicine, the tuber-
culin skin test (TST) [3]. Interferon-c release assays (IGRAs)
have been added to the diagnostic armamentarium. Two
commercial IGRAs are available, the QuantiFERON-TBª
Gold In-Tube (QFT-GIT; Cellestis Limited, Chadstone, Vic.,
Australia) and the T-SPOT.TB (Oxford Immunotec, Abing-
don, UK).
The use of IGRAs has increased substantially since 2005,
mostly in low-incidence countries. Many studies, meta-
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analyses and systematic reviews have been performed to
assess the role of these tests in the diagnosis of latent and
active TB. Since 2003, several guidelines and position papers
have been published to direct clinical practice. This review is
an attempt to compare and synthesize these guidelines and
recommendations.
Methods
We searched the literature and contacted over 50 experts
from more than 28 countries and at supranational organiza-
tions to identify guidelines or recommendations on the use of
IGRAs. The initial survey was conducted in 2009 and published
as a conference proceeding [4]. This 2009 survey identiﬁed 17
country guidelines. Building on this survey, we updated our
search and contacted experts to identify updated guidelines or
new statements from 2009 to March 2011. Whereas some
countries have guidelines endorsed by their ministries of
health, other countries have recommendations from national
or professional organizations. Some countries have more than
one guideline or position paper from different national organi-
zations or interest groups. Many countries (e.g. USA, Canada,
UK, Switzerland) have published updated versions of their ori-
ginal statements and in these cases we included the most
recent iteration in our survey. Position papers from suprana-
tional organizations, such as World Health Organization
(WHO) and the European Centre for Disease Prevention and
Control (ECDC) were included as well.
Most guidelines were available at least in the form of a
summary statement in English. If an English version was not
available, we either translated the guidelines or asked local
experts or guideline authors for a translation. After summa-
rizing the guidelines, we contacted the experts again with
our summary statement of their respective national guide-
lines and asked them to comment on its accuracy.
Results
In total, 33 guidelines from 25 countries and two supranational
organizations were identiﬁed: USA (Centers for Disease
Control and Prevention (CDC) and American Academy of
Pediatrics (AAP)—The Red Book), [5,6], Canada (Canadian
Tuberculosis Committee) [7], UK (National Institute for
Health and Clinical Excellence) [8], Brazil (Ministry of
Health (MOH)) [9], France (National Authority for Health)
[10], Spain (Spanish Society of Pneumology and Thoracic
Surgery) [11], Italy (MOH) [12,13], Germany (German Central
Committee Against Tuberculosis) [14,15], Austria (personal
communication with national expert) [16], Portugal (MOH)
[17], Ireland (National TB Advisory Committee) [18], Switzer-
land (Swiss Lung Association) [19], the Netherlands (Commit-
tee for Practical Tuberculosis Control) [20], Denmark (Danish
Lung Medical Society) [21], Norway (Norwegian Public Health
Institute) [22], Finland (National Institute for Health and Wel-
fare, personal communication with national expert) [23],
Czech Republic (personal communication with national
expert) [24], Slovakia (MOH, personal communication with
national expert) [25], Poland (national experts) [26], Bulgaria
(personal communication with national expert) [27], Croatia
(personal communication with national expert) [28], Saudi
Arabia (joint statement of professional societies) [29], Austra-
lia (National Tuberculosis Advisory Committee, Australasian
Society for Infectious Diseases, and Australian Rheumatology
Association) [30–32], South Korea (personal communication
with national expert) [33], Japan (Japanese Society for Tuber-
culosis Prevention, personal communication with national
expert) [34], WHO [35,36] and ECDC [37]. Many of these
guidelines are available online at http://www.tbevidence.org.
Brazil, Bulgaria, Korea and Saudi Arabia were the only
moderate-burden to high-burden countries to have published
guidelines on the use of IGRAs. The WHO has issued guide-
lines for the use of IGRAs in resource-constrained settings
in HIV-infected and non-HIV-infected patients [35,36]. The
ECDC statement also makes a differentiated recommenda-
tion for high-incidence and low-incidence settings [37].
Although no high-burden, low-income country is using IGRAs
in their national TB programmes, these tests are being used
in some high-burden countries (e.g. India, South Africa) in
the private sector and in research settings.
A number of countries and organizations are in the pro-
cess of ﬁnalizing their ﬁrst guidelines or position papers (e.g.
Austria, Bulgaria, Poland and Denmark). Others are updating
them (including Germany and South Korea) and publication
of these guidelines and position papers can be expected in
the coming months.
Across all the guidelines, four main approaches are used
most commonly:
• two-step approach of TST ﬁrst, followed by IGRA
• IGRA only, replacing the TST
• both TST and IGRA together
• either TST or IGRA, but not both.
In the following sections, these different approaches are
examined for speciﬁc indications.
Diagnosis of active tuberculosis
Both the TST and IGRAs are indirect tests that indicate a
cellular immune response to recent or remote sensitization
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with mycobacterial antigens. Neither test can distinguish
between individuals with LTBI, active TB or even past TB. In
a recent meta-analysis of studies in low-income and middle-
income countries assessing the use of IGRAs in active TB,
the pooled sensitivity in HIV-infected patients was 76% for
the T-SPOT.TB assay and 60% for the QFT-GIT. This com-
pared with 83% for T-SPOT.TB and 69% for QFT-GIT in
non-HIV-infected patients. The speciﬁcity estimates of IGRAs
were low for both non-HIV-infected individuals (T-SPOT.TB
61%, QFT-GIT 52%) and HIV-infected individuals (T-
SPOT.TB 52%, QFT-GIT 50%) [38].
Another recent meta-analysis assessing studies from both
high-incidence and low-incidence countries, including children
and HIV-infected individuals, conﬁrmed these ﬁndings, espe-
cially the low speciﬁcity in individuals with suspected TB
[39]. In summary, both systematic reviews concluded that
IGRAs should not be used in the diagnostic investigations of
active TB in adults because a positive IGRA result may not
indicate active TB and likewise, a negative IGRA result may
not rule out active disease.
Most guidelines reﬂect these limitations of IGRAs in
respect to the diagnosis of active TB (Table 1). If IGRAs are
recommended for the diagnosis of active TB, they are clearly
considered to be only an adjunct test in addition to, but not
replacing, the standard microbiological and radiographic tests.
The recently published ECDC guideline summarizes as fol-
lows: ‘‘IGRAs should not replace the standard diagnostic
methods […] for diagnosing active TB. […] However, based
on limited evidence, in certain clinical situations (e.g. patients
with extrapulmonary TB, patients who test negative for acid-
fast bacilli in sputum and/or negative for M. tuberculosis on
culture, TB diagnosis in children, or in the differential diagno-
sis of infection with NTM (nontuberculous mycobacteria))
IGRAs could contribute supplementary information as part
of the diagnostic work-up.’’ [37].
Some guidelines (Canada, Switzerland, Saudi Arabia and
Croatia) explicitly recommend against the use of IGRAs in
the diagnosis of active TB in adults but include them as part
of the diagnostic algorithm in children as tests that provide
evidence of TB infection. This acknowledges the difﬁculty of
diagnosing TB by conventional methods in children [40]. The
WHO recommends against the use of IGRAs for active TB
in low-income and middle-income countries because of the
poor speciﬁcity on account of a high background prevalence
of LTBI [35,36,41,42].
Contact investigation in adults
The role of IGRAs in contract tracing is summarized in
recent systematic reviews [43–46]. The most obvious
strength of IGRAs is their high speciﬁcity, because they allow
the clinician to differentiate between a sensitization caused
by bacillus Calmette–Gue´rin (BCG) vaccination or non-
tuberculous mycobacterial exposure and contact with an
active TB case. However, recent cohort studies suggested
that IGRAs, similar to the TST, have only modest predictive
ability. Only 1–3% of IGRA-positive contacts develop active
TB over 2 years of follow-up, even in high burden countries
[47–51]. This indicates that interferon-c alone is probably
insufﬁcient as a biomarker for disease progression, especially
if only measured at baseline [52,53]. A combination of TST/
IGRA and risk factor information may be more helpful, espe-
cially if made available as web-based algorithms (http://
www.tstin3d.com) [54]. More recently, a World BCG Atlas has
been published (http://www.bcgatlas.org), to help clinicians
decide on whether to use a TST or an IGRA, depending on
the local BCG policies and practices [55].
The country guidelines on the use of IGRAs in contact
tracing for adults mostly favour a two-step testing approach
(Table 2). A TST is performed in the ﬁrst step and if posi-
tive, it is followed up with an IGRA. The two-step approach
TABLE 1. Guidelines on interferon-
c release assays (IGRAs): recom-
mendations for active tuberculosis
Recommendation Subgroup Guideline or position statementa
For the use of IGRAs but
only as an adjunct (some
guidelines specify the use
only when other diagnostic
tests have been unrevealing)
In adults ECDC, USA-CDC, UK, France (only for
extrapulmonary TB), Australia, Slovakia,
Japan, the Netherlands, Norway, Bulgaria,
Portugal, Denmark, Austria
In children ECDC, Canada, USA (CDC and AAP), UK,
Switzerland, Australia, Slovakia, Japan
(children >12 years of age), Saudi Arabia,
the Netherlands, Norway, Bulgaria, Portugal,
Croatia, Denmark, Austria
Against the use of IGRAs In adults WHO, Canada, Switzerland, Saudi Arabia, Croatia,
Ireland, South Korea, Brazil
In children WHO, France, Ireland, South Korea, Brazil
No recommendations Germany, Italy, Spain, Finland, Poland, Czech Republic
AAP, American Academy of Pediatrics; CDC, US Centers for Disease Control and Prevention; ECDC, European
Centre for Disease Prevention and Control; IGRA, interferon-gamma release assay; TST, tuberculin skin test; WHO,
World Health Organization.
aSome countries/organizations are listed more than once because their recommendations vary across risk groups.
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is primarily intended to increase speciﬁcity in individuals with
prior BCG vaccination, and also to reduce costs incurred by
the follow-up and LTBI treatment of TST false positives.
Some countries recommend only IGRAs for persons with
previous BCG vaccination, whereas others favour the IGRA
in a second step independent of a history of BCG vaccina-
tion. A few country guidelines acknowledge the possibility
that a TST can boost subsequent IGRA results [56] (i.e. Can-
ada, USA, the Netherlands, Germany, Ireland) and some
make speciﬁc recommendations on when the IGRA should
be performed in relation to the TST (i.e. on the day of read-
ing of the TST or within 3 days of the TST placement).
Some guidelines suggest that either an IGRA or a TST
should be used for contact investigation (USA, Denmark,
South Korea, Finland, Austria). Some of these (i.e. USA,
Denmark, Finland) specify certain subgroups in which the
IGRA should be used preferentially (i.e. persons who refuse
to accept the TST, BCG-vaccinated individuals and individuals
who are unlikely to return for the second visit required for
a TST). Some countries suggest using the IGRA only (Slova-
kia, Japan, France) or in addition to the TST (Czech Republic,
Austria, Croatia). The Australian guidelines suggest using the
IGRA ‘‘as a supplementary test in individualised clinical
assessment’’ [30]. Similarly, Canada uses a differentiated
approach based on the risk of the patient [7]. For individuals
with a high-risk exposure or a high-risk for progression to
active TB, both tests are carried out to increase sensitivity,
whereas for all others the sequential approach is taken with
the TST performed ﬁrst.
The WHO issued a recommendation against the use of
IGRAs and for the use of TST, but only in low- and
middle-income settings, regardless of HIV status [35,36]. The
ECDC has a differentiated approach based on TB-incidence.
In a high-incidence setting, the ECDC concurs with the
WHO and suggests only a TST, whereas for low-incidence
settings a two-step approach is recommended [37]. Overall,
the recommendations for contact tracing in adults appear to
suggest a clear trend towards an increased use of IGRAs,
especially in low-incidence countries, mostly as a two-step
strategy.
Contact tracing in children
There are limited data on the use of IGRAs for the diagnosis
of LTBI in children. The data are especially sparse in the very
young children, and very few studies have assessed the pre-
dictive value of IGRAs in children. Two recent meta-analyses
concluded that TST and IGRAs have similar accuracy for the
detection of TB infection or the diagnosis of disease in chil-
dren [43,57].
Guidelines regarding children are very heterogeneous and
reﬂect the uncertainties in the evidence base (Table 3). Many
continue to prefer a TST alone, either for all children
(WHO, ECDC, Brazil, Switzerland, France) or only for chil-
dren under 5 years of age (Canada, Japan, Ireland, USA-CDC
and USA-AAP). Treatment for LTBI based on a positive TST
result only, regardless of BCG vaccination or even if a TST
TABLE 2. Guidelines on IGRAs: recommendations for con-
tact investigation in adults
Recommendation Guideline or position statementa
TST alone WHO, Brazil, ECDC (high-incidence
countries)
TST followed by IGRA,
if TST positive (either IGRA
only in BCG-vaccinated
persons or independent
of BCG vaccine)
Canada (low-risk contacts), Germany, Italy,
Switzerland, Spain, Saudi Arabia, the
Netherlands, Norway, Bulgaria, Portugal,
Ireland, ECDC (low-incidence countries),
and for UK and South Korea only in
adults <35 years old
Both TST and IGRA Canada (high-risk contacts), Czech Republic,
Croatia, Austria, Australia (IGRA may be
considered in addition)
Either TST or IGRA USA, Denmark, Finland (IGRA preferred if
BCG-vaccinated in all three countries),
South Korea (only in adults <35 years old),
Austria
IGRA alone Slovakia, Japan, France
BCG, bacille Calmette–Gue´rin; CDC, US Centers for Disease Control and Pre-
vention; ECDC, European Centre for Disease Prevention and Control; IGRA,
interferon-gamma release assay; TST, tuberculin skin test; WHO, World Health
Organization.
aSome countries/organizations are listed more than once because their recom-
mendations vary across risk groups.
TABLE 3. Guidelines on IGRAs: recommendations for con-
tact investigation in children
Recommendation Guideline or position statementa
TST alone WHO, ECDC, France, Brazil, Switzerland
(IGRA in addition only in case of doubt),
Slovakia (in BCG non-vaccinated children),
South Korea (for children <5 years old)
TST alone (in children
0–4 years old); TST
followed by IGRA, if
TST positive (for
children 5–17 years old)
Canada (low-risk contacts), Japan,
Ireland, USA-AAP (for children
>5 years old, IGRA may also replace TST)
TST followed by IGRA,
if TST positive
Germany, Italy, Spain, Saudi Arabia, the
Netherlands (dependent on BCG
vaccination status and result of TST, only
TST might be sufﬁcient), Bulgaria, and for
children >5 years of age only in Portugal
and UK
TST followed by IGRA,
if TST negative
Portugal (for children <5 years old), UK
(for children 2–5 years old)
Either TST or IGRA Denmark, USA-CDC (but TST is preferred
in children <5 years old), South Korea (for
children >5 years old, but TST preferred),
Finland
Both TST and IGRA Canada (high-risk contacts), Czech Republic,
Croatia, Australia (IGRA may be
considered in addition for
children >2 years old)
IGRA alone Norway
AAP, American Academy of Pediatrics; BCG, bacille Calmette–Gue´rin; CDC, US
Centers for Disease Control and Prevention; ECDC, European Centre for Dis-
ease Prevention and Control; IGRA, Interferon-gamma release assay; TST,
tuberculin skin test; WHO, World Health Organization.
aSome countries/organizations are listed more than once because their recom-
mendations vary across risk groups.
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is negative but a high clinical suspicion persists, is justiﬁed by
the fact that young children are at high risk for progression
to active TB. Most other guidelines recommend a TST in
combination with an IGRA if the TST is positive, especially
for BCG-vaccinated children (Germany, Italy, Spain, Saudi
Arabia, the Netherlands, Bulgaria).
Some statements limit the two-step testing to children
over 5 years of age (Canada, Japan, Portugal, UK, Ireland and
USA-AAP) given the limited amount of data on IGRAs in
very young children. The Red Book (USA-AAP), while favour-
ing a two-step approach, also allows the use of IGRAs
replacing the TST for children older than 5 years of age. The
guidelines using an approach with either a TST or an IGRA
include the USA-CDC (TST favoured for children <5 years
of age), Denmark, South Korea (TST only recommended for
children <5 years of age and favoured for children >5 years
of age) and Finland. A few countries recommend both tests
together (Canada—for high-risk contacts, Czech Republic
and Croatia) or suggest that an IGRA may be used as a sup-
plementary test (Australia, for children >2 years of age) or if
initial TST is negative (Portugal for children <5 years of age,
UK for children 2–5 years of age).
Immunocompromised: individuals with HIV infection
Individuals who are HIV-positive are at high risk of progres-
sion from LTBI to active TB and therefore are an important
group for LTBI screening [36,58]. Data on the use of IGRAs
in people living with HIV were summarized in a recent sys-
tematic review [59]. The sensitivity estimate in HIV-infected
patients with culture-conﬁrmed TB was higher for
T-SPOT.TB (72%) than for QFT-GIT (61%). However,
neither IGRA was consistently more sensitive than the TST
in head-to-head comparisons. The agreement between the
two IGRAs and TST was higher in the high-income countries
were BCG vaccination was used less frequently.
The meta-analysis also suggested that IGRAs, and espe-
cially the T-SPOT.TB assay, are less affected by HIV-related
immunosuppression than the TST, but the differences
between the tests were small and results varied substantially
across individual studies. Limited data were available on the
predictive value of IGRAs for active TB. Hence, the system-
atic review concluded that IGRAs perform in a similar way
to the TST in identifying HIV-infected individuals who could
beneﬁt from LTBI treatment.
These equivocal data are also reﬂected in the wide array
of different country recommendations (Table 4). The guide-
lines for low-resource and high-TB-incidence settings, the
Brazilian and the WHO guidelines, recommend the TST. The
other guidelines and position papers clearly show a trend
towards a greater use of IGRAs. While the Swiss, French
and Bulgarian guidelines recommend use of IGRA alone,
other countries and organizations (ECDC, Portugal, Slovakia,
the Netherlands, USA, South Korea, Croatia and UK) sug-
gest the use of both tests together (either up front or if the
chosen initial test is negative) to increase the sensitivity. Yet
others suggest a two-step approach with a negative TST fol-
lowed by an IGRA to increase sensitivity (Canada, Italy, Ire-
land, Saudi Arabia and Spain).
Immunocompromised: individuals on anti-tumour necrosis
factor-a therapy
Individuals on tumour necrosis factor-a (TNF-a) inhibitor
therapy are at high risk of progression from LTBI to active
TB [60]. Screening for LTBI is recommended in many coun-
tries before starting TNF-a inhibitors for immune-mediated
inﬂammatory disorders. Few studies have evaluated the per-
formance of IGRAs in screening for LTBI in patients with
these disorders.
Although no meta-analysis has been published, two recent
reviews [61,62] have synthesized the data. Both reviews
were hampered by the substantial heterogeneity between
the studies. The differences in the studies relate to the level
of immunosuppression (pre-TNF-a inhibitors, on TNF-a
inhibitor and variable additional steroid use), the types of
TNF-a inhibitors used, the immune-mediated inﬂammatory
disorders treated (IMID), the tests that were evaluated, and
the rate of BCG vaccination in the population. In addition,
the small numbers of patients with conﬁrmed TB disease and
the lack of any data on the predictive value of IGRA limited
the studies. The authors concluded that the current evidence
does not suggest superiority of IGRAs over the TST in iden-
tifying latent TB in individuals with IMID [61].
TABLE 4. Guidelines on IGRAs: recommendations for HIV-
infected populations
Recommendation Guideline or position statementa
TST alone WHO, Brazil
TST followed by IGRA,
if TST positive
(and BCG-vaccinated)
Spain
TST followed by IGRA,
if TST negative
Canada, Italy, Saudi Arabia, Spain, Ireland
Either TST or IGRA Denmark, South Korea, Austria
Both TST and IGRA ECDC, Portugal, Croatia, Slovakia, the
Netherlands, USA (if either initial test
negative), South Korea, UK
IGRA alone Switzerland, Bulgaria, France, UK
(if CD4 200–500)
No speciﬁc recommendations Germany, Czech Republic, Norway,
Japan, Finland, Australia
AAP, American Academy of Pediatrics; BCG, bacille Calmette–Gue´rin; CDC, US
Centers for Disease Control and Prevention; ECDC, European Centre for Dis-
ease Prevention and Control; IGRA, interferon-gamma release assay; TST,
tuberculin skin test; WHO, World Health Organization.
aSome countries/organizations are listed more than once because their recom-
mendations vary across risk groups.
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Similar to HIV, the guidelines for LTBI screening for
patients on TNF-a inhibitors reﬂect the lack of deﬁnitive
data (Table 5) and a number of different strategies are rec-
ommended. While the Brazilian guidelines continue to rely
on the TST, several others now favour the IGRAs as the
only test (Germany, Switzerland, Bulgaria, Japan, France,
Poland) and some suggest a TST in addition to the IGRA
only if the IGRA is repeatedly indeterminate or negative (i.e.
Germany). Many guidelines combine both tests to increase
sensitivity (ECDC, USA, Portugal, Czech Republic, Croatia,
Slovakia, the Netherlands, South Korea, Ireland and UK)
either upfront or if the initially chosen test is negative. Alter-
natively, a two-step approach with an IGRA following a TST,
if the TST is negative, is recommended to increase sensitivity
but limit cost (Canada, Italy, Spain, Saudi-Arabia).
Screening of immigrants
In low-incidence countries, a majority of the TB cases occur
among recent immigrants and foreign-born persons [2,63],
and immigrant screening is often a key component of TB
control. Most guidelines that include recommendations are
from countries with low-incidence (Table 6) and focus on
immigrants from high-incidence settings but others also
include recommendations for immigrants who are likely to
develop active disease (i.e. children or persons with underly-
ing disease that predisposes them to a reactivation of an
LTBI) independent of their country of origin (e.g. Canada,
the Netherlands).
All guidelines that do make recommendations for screen-
ing of immigrants incorporate IGRAs. The most common
algorithm is a TST followed by an IGRA if positive (UK (for
children 5–15 years of age), Italy, Switzerland, Spain, the
Netherlands, Norway, Ireland, France, Slovakia and Bulgaria).
This algorithm is intended to increase speciﬁcity given the
widespread use of BCG vaccination in countries where TB is
endemic.
Serial testing of healthcare workers
The value of IGRAs in the testing of healthcare workers has
been investigated in over 50 studies, which are summarized in
a recent systematic review [64]. The review differentiates
between initial testing (e.g. pre-employment) and serial
(repeated) testing of healthcare workers. Overall, the review
concluded that the use of IGRAs instead of TST for one-time
screening may result in a lower prevalence of positive tests
and fewer healthcare workers who require LTBI treatment,
particularly in settings where TB incidence is low. However,
the use of IGRAs for serial testing is complicated by the lack of
data on optimal cut-offs for serial testing and unclear interpre-
tation and prognosis of conversions and reversions [64].
This uncertainty is also reﬂected in the guidelines
(Table 7). Many guidelines and position papers do not make
recommendations for the serial screening of healthcare
workers (Australia, Czech Republic, Norway, Croatia,
Denmark, Germany, UK, Finland and ECDC). Some countries
suggest the use of IGRAs only (Slovakia, Japan, the Nether-
lands, Portugal, France) or as an alternative to the TST (USA,
Switzerland, Italy) for serial healthcare worker screening.
Some of the guidelines comment on the limitations of the
IGRAs for serial testing. For example, the Canadian guideline
states that ‘‘there is insufﬁcient published evidence to recom-
mend serial IGRA testing in populations exposed to TB, such
as healthcare workers or prison staff and inmates’’ [7]. The
TABLE 5. Guidelines on IGRAs: recommendations for LTBI
screening in persons on TNF-a inhibitors
Recommendation Guideline or position statementa
TST alone Brazil
TST followed by IGRA,
if TST positive
Spain, Norway
TST followed by IGRA,
if TST negative
Canada, Italy, Spain, Saudi Arabia
Either TST or IGRA Australia-ARA, Denmark (IGRA favoured),
South Korea
Both TST and IGRA ECDC, UK (alternatively IGRA alone), USA
(if either initial test negative), Portugal,
Croatia, Czech Republic, Slovakia, the
Netherlands, South Korea, Ireland
(TST preferred)
IGRA alone Germany, Switzerland, Bulgaria,
Japan, France, Poland, Austria
No recommendations Finland, Australia-NTAC
ARA, Australia Rheumatology Association; CDC, US Centers for Disease Con-
trol and Prevention; ECDC, European Centre for Disease Prevention and Con-
trol; IGRA, interferon-gamma release assay; NTAC, National Tuberculosis
Advisory Committee, Australia; TST, tuberculin skin test; WHO, World Health
Organization.
aSome countries/organizations are listed more than once because their recom-
mendations vary across risk groups.
TABLE 6. Guidelines on IGRAs: recommendations for
screening of immigrants
Recommendation Guideline or position statementa
TST followed by IGRA,
if TST positive
UK (for children age 5–15 years), Italy,
Switzerland, Spain, Norway, Ireland,
Bulgaria, France (in children), Slovakia, the
Netherlands (for children only; dependent
on BCG vaccination status and result of
TST, only TST might be sufﬁcient)
Both TST and IGRA Czech Republic, UK (for adults age
16–35 years; or IGRA alone alternatively)
Either TST or IGRA USA (IGRA preferred in BCG-vaccinated
persons), Canada, Australia
IGRA alone France (in adults)
No recommendations/
not recommended
Germany, Japan, Saudi Arabia,
Brazil, Portugal, Croatia, Denmark, South
Korea, Finland, Poland, Austria
BCG, bacille Calmette–Gue´rin; CDC, US Centers for Disease Control and Pre-
vention; ECDC, European Centre for Disease Prevention and Control; IGRA,
interferon-gamma release assay; TST, tuberculin skin test; WHO, World Health
Organization.
aSome countries/organizations are listed more than once because their recom-
mendations vary across risk groups.
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CDC guideline states that ‘‘the criteria for interpreting
changes in an IGRA that identify new infections remain
uncertain’’ [5]. Because of such concerns, many countries
actually favour a TST only (Brazil, South Korea, Canada,
Saudi Arabia, Ireland, Austria), or a TST with a second-step
IGRA if the TST is positive (Spain, the Netherlands,
Bulgaria).
Conclusion
A growing number of guidelines and position papers now
address the use of IGRAs. Overall, the use of IGRAs is
increasingly recommended, primarily in low-incidence
settings, but there is considerable diversity in the recommen-
dations on how exactly IGRAs should be used. In high-
incidence and low-resource countries, the TST is still
favoured because there is no strong evidence that IGRAs are
superior to the TST in such settings, especially given the
signiﬁcantly higher costs associated with IGRAs. In low-
incidence and high-resource settings, the higher speciﬁcity of
IGRAs and their logistical advantages seem to enhance their
adoption and usage.
One reason for the heterogeneity among guidelines is that
conclusive data to inform these guidelines were often limited,
particularly with the older guidelines. This is true especially
with respect to the use of IGRAs in patients starting TNF-a
inhibitors or in children younger than 5 years of age. Until
recently, there were few cohort studies on the predictive
value of IGRAs and this may have further inﬂuenced guide-
lines and statements.
Whereas most guidelines (78%) cited systematic reviews
of available data, most (70%) did not use objective and trans-
parent grading systems (e.g. GRADE [65]) for guideline
development. A majority of the guidelines did not include
statements on conﬂict of interest. These ﬁndings are consis-
tent with published data on poor methodological quality of
TB guidelines [66]. On the positive side, several countries
have attempted to update their guidelines, as the evidence
base on IGRAs has steadily matured. To have an impact,
future IGRA guidelines must be transparent, evidence-based,
periodically updated and free of ﬁnancial conﬂicts and indus-
try involvement.
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